Background/Objectives: Proficiency of performing sentinel lymph node biopsy (SLNB) for breast cancer varies among hospitals and may be reflected in the hospital's SLNB positivity rate. Our objectives were to examine whether hospital characteristics are associated with variation in SLNB positivity rates and whether hospitals with lower-than-expected SLNB positivity rates have worse patient survival.
Methods: Using the National Cancer Data Base, stage I to III breast cancer patients were identified (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Hospital-level SLNB positivity rates were adjusted for tumor and patient factors. Hospitals were divided into terciles of SLNB positivity rates (lower-, higher-, as-expected). Hospital characteristics and survival were examined across terciles.
Results: Of 438 610 SLNB patients (from 1357 hospitals), 78 104 had one or more positive SLN (21.3%). Hospitals in the low and high terciles were more likely to be low volume (low: RRR, 4.40; 95% CI, 2.89-6.57; P < 0.001; and high: RRR, 1.79; 95% CI, 1.21-2.64; P < 0.001) compared to hospitals with as-expected (middle tercile) SLNB positivity rates. Stage I patients at low-and high-tercile hospitals had statistically worse survival.
Conclusions: There is a wide variation in hospital SLNB positivity rates. Hospitals with lower-or higher-than-expected SLNB positivity rates were associated with survival differences. Hospital SLNB positivity rates may be a novel 'process measure' to report to hospitals for internal quality assessment.
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| INTRODUCTION
Over 250 000 women were diagnosed with breast cancer in 2016. 1 It is estimated that one-fourth of these newly diagnosed breast cancer cases are expected to present with lymph node metastases. 2 Development of practical methods of sentinel lymph node identification for breast cancer in the 1990s has resulted in widespread use of sentinel lymph node biopsy (SLNB) as an indicator of the status of the regional axillary lymph nodes.
Though SLNB can be learned without excessive difficulty by most surgeons, Morton, 3 and Cox et al 2 have commented on the "learning curve" inherent in mastering the procedure. Proper identification of the SLN requires multidisciplinary expertise within a single institution, including not only a surgeon trained in the operative technique, but nuclear medicine expertise, and experienced pathologists. 4 Lack of experience or proficiency in any of these areas can lead to low SLN identification rates and elevated false-negative rates. 5 lymph nodes = ALND) as has been previously described. [12] [13] [14] The results of the analyses were similar using either approach and thus only results using the "scope regional lymph nodes examined" defined variable recorded in the NCDB are shown. Hospital characteristics evaluated included hospital type NCI accredited, non-NCI academic, and community), SLNB volume (quartiles using the median number of SLNB performed each year at each hospital during the study period), and population density (metropolitan, urban/rural, and unknown).
| Analytic variables

| Statistical analysis
Catergorical variables by nodal positivity were examined using the Next, we performed a hospital-level analysis. The SLNB positivity estimate for each patient at a hospital was summed and then combined with the summed observed positivity rate to calculate an observed-toexpected (O:E) lymph node positivity ratio for each hospital. This hospital SLNB positivity rate was the primary outcome of the study. For analysis, hospitals were divided into terciles (lower-than-expected positivity rate, as-expected positivity rate, and higher-than-expected positivity rate).
We used multinomial logistic regression models to determine which hospitals had O:E ratios in the low-and high-tercile groups compared to the middle-tercile group. Predictors of being in the top or bottom tercile, compared to the middle tercile, such as hospital type, SLNB volume per year, and population density was estimated.
A secondary outcome measure was 5-year overall survival. As the NCDB has follow-up data for 5 years after diagnosis, outcomes were To test the association between lower-or higher-than-expected hospital SLNB positivity rates (low-and high-tercile hospitals, respectively) and time to recurrence or death after stratifying for AJCC stage, Cox proportional hazards models were developed. An increased risk of death was indicated by a hazard ratio of less than 1.0.
The level of statistical significance was set at 0.05. All P values reported were based on two-sided tests. Statistical analyses were performed with SAS version 9.4 (SAS, Cary, NC). (Table 2 ). Hospital volume of SLNB was, however, associated with adjusted SLNB positivity rates:
| RESULTS
| Predictors of SLNB positivity at the patient level
hospitals with lower-than-expected SLNB positivity rates more commonly performed the lowest volume of SLNB, while hospitals with as-expected SLNB positivity rates most commonly performed the highest volume of SLNB (P < 0.001) ( Table 2 ). Within as-expected SLNB positivity rate hospitals, the median number of annual SLNBs performed was 33 (IQR, 17-64). The median number of SLNB performed annually in hospitals with lower-than-expected SLNB positivity rates was 20 (IQR, 10-37) SLNBs and was 25 annually (IQR, 13-47) in hospitals with higher-than-expected SLNB positivity rates.
After adjustment for certain hospital characteristics as detailed above, both low-and high-tercile hospitals were more likely to be low volume hospitals when compared to hospitals with as expected (ie, middle-tercile) SLNB positivity rates (low tercile: relative risk ratio (RRR) = 4.36; 95% CI, 2.89-6.57; P < 0.001; high tercile: RRR = 1.79; 95% CI, 1.21-2.64; P < 0.001) ( Table 3) . Hospital type was not a significant predictor of lower-or higher-than-expected (ie, low-or high-tercile) hospital SLNB positivity rates. This was true even after removal of SLNB volume from the hospital-level analysis.
| Survival and SLNB positivity rate
Patients who presented with stage I breast cancer treated at lowerthan-expected SLNB positivity rates hospitals had a statistically worse 
T A B L E 2 Hospital characteristics by SLNB positivity O:E ratio
| DISCUSSION
Few process measures in surgery address the quality of the procedure itself, which may be particularly important in oncologic procedures.
Instead, most process measures used for quality measurement in surgery focus on aspects of perioperative care such as receipt of venous thromboembolism prophylaxis and use of appropriate antibiotics to help prevent surgical site infections. 16 The objective of this study was to illustrate the national variation in breast cancer surgery SLNB positivity rates at the hospital level and to determine whether breast cancer surgery SLNB positivity rates are a potentially novel and helpful measure for quality assessment in breast cancer care. In our study, SLNB positivity rates widely varied across hospitals, and low volume hospitals had lowerthan-expected (potentially false-negative) or higher-than-expected (potentially false-positive) SLNB positivity rates. In addition, undergoing surgery at hospitals with lower-and higher-than-expected SLNB positivity rates were associated with statistically worse 5-year survival in stage I breast cancer patients.
While some studies have demonstrated that increased surgeonlevel volume of SLNB performed for breast cancer improves SLN identification and false-negative rates, 6, 17 there has been no such evaluation of SLNB positivity rates at the hospital level in breast cancer.
We found that low hospital SLNB volume, but not hospital type, was a significant predictor of whether a hospital had a lower-or higher-thanexpected SLNB positivity rate. While this finding has been demonstrated in melanoma, this the first report of SLNB surgical volume affecting hospital-level SLNB positivity rates in breast cancer patients. 8 It has been previously demonstrated that patients who undergo procedures performed at NCI-designated hospitals have improved survival compared to non-NIC hospitals. 18, 19 This designation was not a predictor of SLNB positivity rate in this study. Every hospital in our study was CoC-accredited. CoC-accredted hospitals tend to focus on delivering high-quality cancer care, are often affiliated with a medical school, and hold Joint Commission accreditation when compared to non-CoC-accredited hospitals. 20 In addition, CoCaccredited hospitals must follow their patients over time and record their survival. 21 Therefore, CoC-accredited hospitals and NCIdesignated hospitals may not have significantly different cancer outcomes as they most likely provide similar care to their patients, a finding consistent with a prior study that demonstrated a difference in mortality between NCI-designated hospitals and CoC-accredited hospitals only for high-risk procedures and patients. 22 We found that patients with stage I breast cancer treated at hospitals with both lower-and higher-than-expected SLNB positivity rates hospitals had significantly worse 5-year overall survival rates compared to patients treated at hospitals with as-expected SLNB positivity rates.
Though the magnitude of the survival difference was small, it was statistically significant and represents a substantial absolute number of lives since breast cancer is the most common cancer in women in the and lack of granularity of certain variables in the NCDB (eg, the exact origin of lymph nodes harvested from a dissection) may have affected the results of our study. In particular, some specifics regarding the SLNB variable (inability to capture whether an SLNB was attempted and aborted, whether an SLNB had been performed before a cALND at a non-CoC hospital), could have affected our findings. While the NCDB represents a high-quality data set, variable selection and granularity represent areas in continual evolution and improvement. 30 The accuracy of an SLNB is crucial to appropriately caring for patients with breast cancer. Because SLNB quality is affected by multiple people and departments at a hospital (eg, surgery, pathology, and nuclear medicine), the SLNB positivity rate of a hospital captures a broad picture of the hospital-level quality of SLNB rather than SLNB quality at the level of the individual surgeon. Thus, using SLNB positivity as a surgeon-level quality measure would be inappropriate, as previous studies have demonstrated that the experience of the surgeon, pathologist, and technical assistance are known to affect the false-negative rate in SLNB. 5, 8, 18, 31, 32 However, alerting hospitals when their hospitallevel SLNB positivity rates are higher-or lower-than−expected could prompt them to investigate their techniques and protocols for SLNB, and identify concrete steps in specific areas or specialties (eg, nuclear medicine protocols, surgeon technical skill, or pathologic analysis) to improve SLNB accuracy.
| CONCLUSION
Adjusted SLNB positivity rates for patients with breast cancer vary widely across hospitals, and this variation has a strong association with the volume of SLNB procedures performed at the hospital. Lower-and higher-than-expected hospital-level SLNB positivity rates are associated with low SLNB volumes and worse overall 5-year survival. Although it is not recommended that this measure is used for public reporting or payfor-performance until it is further investigated and validated, the NCDB has the ability to notify hospitals of their SLNB positivity rate and whether their rate is lower-or higher-than−expected one, for use internally. 33 Thus, hospital-level SLNB positivity rate could potentially be utilized as a quality metric that would allow hospitals to identify deficiencies in care and develop quality improvement projects to improve SLNB at their institutions.
